Viking Therapeutics
VKTX
134 hedge funds and large institutions have $238M invested in Viking Therapeutics in 2021 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 40 increasing their positions, 47 reducing their positions, and 12 closing their positions.
476% more call options, than puts
Call options by funds: $8.98M | Put options by funds: $1.56M
5% more capital invested
Capital invested by funds: $227M → $238M (+$11M)
0.19% less ownership
Funds ownership: 48.49% → 48.3% (-0.19%)
3% less funds holding
Funds holding: 138 → 134 (-4)
15% less repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 47
25% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
N
Nuveen
Charlotte,
North Carolina
|
+$5.13M |
| 2 |
Dimensional Fund Advisors
Austin,
Texas
|
+$2.66M |
| 3 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$1.99M |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$635K |
| 5 |
First Trust Advisors
Wheaton,
Illinois
|
+$611K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$5.83M |
| 2 |
Citigroup
New York
|
-$1.21M |
| 3 |
Morgan Stanley
New York
|
-$1.18M |
| 4 |
Goldman Sachs
New York
|
-$935K |
| 5 |
ACM
ACT Capital Management
Wayne,
Pennsylvania
|
-$770K |
VKTX Hedge Fund Activity: Q3 2021 in Review
134 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Viking Therapeutics (VKTX) for Q3 2021, worth a combined $238M — up 4.9% from $227M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of VKTX and 9 opened new positions — a net loss of 3 holders — while 47 trimmed existing stakes and 40 added.
The largest buyer was Nuveen, adding an estimated $5.13M. The largest seller was State Street, cutting an estimated $5.83M.
- 134 institutional investors held Viking Therapeutics (VKTX) as of Q3 2021, down from 138 in Q2 2021.
- Funds reported $238M of Viking Therapeutics stock for Q3 2021, up 4.9% quarter-over-quarter.
- 9 funds opened new Viking Therapeutics positions in Q3 2021 and 12 closed out, a net change of -3 holders.
- The largest Viking Therapeutics buyer in Q3 2021 was Nuveen, an estimated $5.13M added.
- The largest Viking Therapeutics seller in Q3 2021 was State Street, an estimated $5.83M sold.
Based on aggregated 13F filings for Q3 2021.